 Director Since: 2017
Age: 59
 Chief Executive Officer Director Since: 2018
Age: 57
 Director Since: 1997
Age: 71
 Director Since: 2015
Age: 62
 Director Since: 2007
Age: 71
 Lead Independent Director Director Since: 2013
Age: 55
 Director Since: 2007
Age: 61
 Executive Chairman Director Since: 2010
Age: 65
 Director Since: 2014
Age: 59
BOARD COMPOSITION
Ronald E. Blaylock Director Since: 2017
Age: 59
Independent: Yes
Other Current Public Boards:
CarMax, Inc., Urban One, Inc. and W.R. Berkley, Inc. Ronald E. Blaylock
Founder, Managing Partner of GenNx360 Capital Partners, a private equity firm focused on investing in industrial and business services companies in the U.S. middle market, since 2006. Prior to launching GenNx360 Capital Partners, Mr. Blaylock founded and managed Blaylock & Company, an investment banking firm. Also held senior management positions at UBS, PaineWebber Group and Citicorp. Director of CarMax, Inc., Urban One, Inc. (formerly Radio One, Inc.) and W.R. Berkley, Inc., an insurance holding company. Director of Syncreon U.S., a for-profit private company. Member of the Board of Trustees of Carnegie Hall. Member of the Board of Overseers of New York University Stern School of Business. KEY SKILLS AND EXPERIENCE:
Business Leadership & Operations/Risk
Management:
Finance & Accounting: Albert Bourla, DVM, Ph.D. Chief Executive Officer Director Since: 2018
Age: 57
Independent: No
Key Skills:
Other Current Public Boards:
None Albert Bourla, DVM, Ph.D.
Chief Executive Officer of Pfizer since January 2019; Chief Operating Officer of Pfizer from January 2018 to December 2018; Group President, Pfizer Innovative Health from June 2016 until December 2017; Group President, Global Innovative Pharma Business of Pfizer from February 2016 until June 2016 (responsible for Vaccines, Oncology and Consumer Healthcare since 2014). President and General Manager of Established Products Business Unit of Pfizer from 2010 until 2013. Area President Europe, Africa, Asia and Pacifc of Pfizer Animal Health from 2009 until 2010. Area President Europe, Africa and Middle East of Pfizer Animal Health from 2005 until 2009. Since joining Pfizer in 1993, Dr. Bourla has served in various leadership positions with increasing responsibility within Pfizer’s former Animal Health and global commercial organizations. Board member of Pharmaceutical Research and Manufacturers of America (PhRMA). Board member of the Pfizer Foundation, which promotes access to quality healthcare. Member of the Board of the Partnership for New York City and Catalyst, a global nonprofit organization accelerating progress for the advancement of women in leadership. KEY SKILLS AND EXPERIENCE:
Business Leadership & Operations/Human
Capital Management/International
Business/Healthcare & Pharma:
Medicine & Science: W. Don Cornwell Director Since: 1997
Age: 71
Independent: Yes
Key Skills:
Other Current Public Boards:
American International Group, Inc. and Avon Products, Inc. W. Don Cornwell
Chairman of the Board and Chief Executive Officer of Granite Broadcasting Corporation (Granite) from 1988 until his retirement in August 2009, and served as Vice Chairman of the Board until December 2009. Director of American International Group, Inc. and Avon Products, Inc. Director of Blue Meridian Partners and Trustee of Big Brothers Big Sisters of New York City. Former Director of CVS Caremark (including two years as Chair of its Compensation Committee) for over 10 years. KEY SKILLS AND EXPERIENCE:
Business Leadership & Operations/Human
Capital Management/Risk Management:
Finance & Accounting: Joseph J. Echevarria Director Since: 2015
Age: 62
Independent: Yes
Key Skills:
Other Current Public Boards:
The Bank of New York Mellon Corporation, Unum Group and Xerox Corporation Joseph J. Echevarria
Chief Executive Officer of Deloitte LLP (Deloitte), a global provider of professional services, from 2011 until his retirement in 2014. During his 36-year tenure with Deloitte, served in various leadership roles, including Deputy Managing Partner, Southeast Region Audit Managing Partner and U.S. Managing Partner and Chief Operating Officer. Director of The Bank of New York Mellon Corporation, Unum Group, a provider of financial protection benefits, and Xerox Corporation. Member of the President’s Export Council and former member of the Presidential Commission on Election Administration. Former Chair of My Brother’s Keeper Alliance. Member of the Board of Trustees of the University of Miami. KEY SKILLS AND EXPERIENCE:
Business Leadership & Operations/International Business/Risk Management:
Finance & Accounting:
Government & Public Policy: Helen H. Hobbs, M.D.  Director Since: 2011
Age: 66
Independent: Yes
Key Skills:
Other Current Public Boards:
None Helen H. Hobbs, M.D.
Investigator, the Howard Hughes Medical Institute since 2002, Professor of Internal Medicine and Molecular Genetics and Director of the McDermott Center for Human Growth and Development at the University of Texas Southwestern Medical Center. Member of the American Society for Clinical Investigation and the Association of American Physicians. Elected to the National Academy of Medicine in 2004, the American Academy of Arts and Sciences in 2006, and the National Academy of Sciences in 2007. Received both the Clinical Research Prize (2005) and Distinguished Scientist Award (2007) from the American Heart Association. In 2012, received the inaugural International Society of Atherosclerosis Prize. Received: the Pearl Meister Greengard Award and the Breakthrough Prize in Life Sciences (2015); the Passano Award (2016); the Harrington Prize for Innovation in Medicine (2018); the Lefoulon-Delalande Grand Prize in Science (2018); the Gerald D Aurbach Award for Outstanding Translational Research (2019); and the Anitschkow Prize (2019). KEY SKILLS AND EXPERIENCE:
Academia/Medicine & Science/Healthcare & Pharma: James M. Kilts Director Since: 2007
Age: 71
Independent: Yes
Other Current Public Boards:
MetLife, Inc., The Simply Good Foods Company and Unifi, Inc. James M. Kilts
Founding Partner, Centerview Capital, a private equity firm, since 2006. Vice Chairman, The Procter & Gamble Company (Procter & Gamble), from 2005 to 2006. Chairman and Chief Executive Officer, The Gillette Company (Gillette), from 2001 to 2005 and President, Gillette, from 2003 to 2005. President and Chief Executive Officer, Nabisco Group Holdings Corporation (Nabisco), from 1998 until its acquisition in 2000. Director of MetLife, Inc., The Simply Good Foods Company and Unifi, Inc. Executive Chairman of the Board of Conyers Park Acquisition Corporation from 2016 until its merger with The Simply Good Foods Company in 2017. Non-Executive Director of the Board of Nielsen Holdings PLC from 2006 until 2017, Chairman of the Board of Nielsen Holdings from 2011 until 2013 and Chairman of the Nielsen Company B.V. from 2009 until 2014. Chairman of Big Heart Pet Brands until 2015 and Director of MeadWestvaco Corporation until 2014. Life Trustee of Knox College and Trustee of the University of Chicago. Member of the Board of Overseers of Weill Cornell Medicine and Founder and Co-Chair, Steering Committee, of the Kilts Center for Marketing at the University of Chicago Booth School of Business. KEY SKILLS AND EXPERIENCE:
Business Leadership &
Operations/International Business:
Healthcare & Pharma: Dan R. Littman, M.D., Ph.D.  Director Since: 2018
Age: 66
Independent: Yes
Key Skills:
Other Current Public Boards:
None Dan R. Littman, M.D., Ph.D.
Helen L. and Martin S. Kimmel Professor of Molecular Immunology at the Skirball Institute of Biomolecular Medicine of NYU Langone Medical Center since 1995 and an Investigator of the Howard Hughes Medical Institute since 1987. Professor of Microbiology and Immunology at the University of California, San Francisco from 1985 to 1995. Member of the National Academy of the Sciences and the Institute of Medicine. Fellow of the American Academy of Arts and Sciences and the American Academy of Microbiology. Founding Scientific Advisory Board Member of Vedanta Biosciences and Vor Biopharma. Member of Scientific Advisory Boards at ChemoCentryx, Inc., the Cancer Research Institute and the Ragon Institute of MGH, MIT and Harvard. Founder and a scientific advisor to Orca Pharmaceuticals. Awarded the New York City Mayor’s Award for Excellence in Science and Technology (2004), the Ross Prize in Molecular Medicine (2013) and the Vilcek Prize in Biomedical Science (2016). KEY SKILLS AND EXPERIENCE:
Medicine & Science/Healthcare &
Pharma/Academia: Shantanu Narayen Lead Independent Director Director Since: 2013
Age: 55
Independent: Yes
Key Skills:
Other Current Public Boards:
Adobe Systems Incorporated Shantanu Narayen
Chairman, President and Chief Executive Officer of Adobe Systems Incorporated (Adobe), a producer of creative and digital marketing software. Prior to his appointment as CEO in 2007, held various leadership roles at Adobe, including President and Chief Operating Officer, Executive Vice President of Worldwide Products, and Senior Vice President of Worldwide Product Development. President of the Board of Adobe Foundation, which funds philanthropic initiatives around the world. Vice Chairman of US-India Strategic Partnership Forum. Named one of the world’s best CEOs by Barron’s magazine in 2016, 2017 and 2018. KEY SKILLS AND EXPERIENCE:
Business Leadership &
Operations/International
Business/Finance & Accounting/Human
Capital Management:
Technology/Risk Management: Suzanne Nora Johnson Director Since: 2007
Age: 61
Independent: Yes
Key Skills:
Other Current Public Boards:
American International Group, Inc., Intuit Inc. and Visa Inc. Suzanne Nora Johnson
Retired Vice Chairman, Goldman Sachs Group, Inc. (Goldman Sachs), since 2007. During her 21-year tenure with Goldman Sachs, served in various leadership roles, including Chair of the Global Markets Institute, Head of Global Research, and Head of Global Health Care. Director of American International Group, Inc., Intuit Inc. and Visa Inc. Co-Chair, Board of Trustees of The Brookings Institution; Co-Chair of the Board of Trustees of the Carnegie Institution of Washington and Co-Chair of the Investment Committee of the Board of Trustees of the University of Southern California. KEY SKILLS AND EXPERIENCE:
Business Leadership & Operations/Risk
Management/International Business:
Finance & Accounting:
Healthcare & Pharma: Ian C. Read Executive Chairman Director Since: 2010
Age: 65
Independent: No
Key Skills:
Other Current Public Boards:
Kimberly-Clark Corporation Ian C. Read
Executive Chairman of Pfizer since January 2019; Chairman of the Board and Chief Executive Officer from December 2011 to December 2018. President and Chief Executive Officer from December 2010 until December 2011. Previously, he served as Senior Vice President and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. In that role, he oversaw five global business units—Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets. Chair of the Pfizer Foundation. Director of Kimberly-Clark Corporation. KEY SKILLS AND EXPERIENCE:
Business Leadership &
Operations/International Business/Healthcare
& Pharma/Finance & Accounting/Government
& Public Policy/Human Capital Management/Risk Management: James C. Smith Director Since: 2014
Age: 59
Independent: Yes
Key Skills:
Other Current Public Boards:
Thomson Reuters Corporation James C. Smith
President, Chief Executive Officer and Director of Thomson Reuters Corporation, a provider of intelligent information for businesses and professionals, since 2012, and its Chief Operating Officer from September 2011 to December 2011 and Chief Executive Officer, Thomson Reuters Professional Division, from 2008 to 2011. Prior to the acquisition of Reuters Group PLC by The Thomson Corporation (Thomson) in 2008, served as Chief Operating Officer of Thomson and as President and Chief Executive Officer of Thomson Learning’s Academic and Reference Group. Member of the International Business Council of the World Economic Forum, the International Advisory Boards of British American Business and the Atlantic Council. KEY SKILLS AND EXPERIENCE:
Business Leadership & Operations/Finance &
Accounting/Human Capital Management/International Business:
Audit Committee Meetings Held in 2018: 11 Audit Committee(1) The Audit Committee is primarily responsible for:
The Audit Committee also is directly responsible for the appointment, compensation, retention and oversight of our independent registered public accounting firm. The Audit Committee has established policies and procedures for the pre-approval of all services provided by the independent registered public accounting firm. The Audit Committee also has established procedures for the receipt, retention and treatment, on a confidential basis, of complaints received by Pfizer regarding its accounting, internal controls and auditing matters. Further details of the role of the Audit Committee, as well as the Audit Committee Report, may be found in "Item 2—Ratification of Selection of Independent Registered Public Accounting Firm" on page 43. The Audit Committee Charter is available on our website at
(1) Effective as of the 2019 Annual Meeting, Dr. Ausiello will retire from the Board and as a member of the Audit Committee, the Regulatory and Compliance
Committee and the Science and Technology Committee.
Compensation Committee Meetings Held in 2018: 6 Compensation Committee The Compensation Committee reviews and approves the company’s overall compensation philosophy and oversees the administration of Pfizer’s executive compensation and benefit programs, policies and practices. Its responsibilities also include:
Each Committee member is a “non-employee director” as defined in Rule 16b-3 under the Securities Exchange Act of 1934 and an “outside director” as defined in Section 162(m) of the Internal Revenue Code. The Compensation Committee has the authority to delegate any of its responsibilities to another committee, officer and/or subcommittee, as the Committee may deem appropriate in its sole discretion, subject to applicable law, rules, regulations and New York Stock Exchange (NYSE) listing standards. The Compensation Committee Charter is available on our website at Compensation Committee Interlocks and Insider Participation. During 2018 and as of the date of this Proxy Statement, none of the members of the Compensation Committee was or is an officer or employee of Pfizer, and no executive officer of the company served or serves on the compensation committee or board of any company that employed or employs any member of Pfizer’s Compensation Committee or Board of Directors.
Corporate Governance Committee Meetings Held in 2018: 5 Corporate Governance Committee The Corporate Governance Committee oversees the practices, policies and procedures of the Board and its committees. Responsibilities include:
The Committee advises on the structure of Board meetings, recommends matters for consideration by the Board and also reviews, advises on and recommends Director compensation, which is approved by the full Board. The Committee is directly responsible for:
The Committee is also directly responsible for maintaining an informed status on: (i) the company’s lobbying priorities and activities; (ii) company issues related to public policy, including political spending policies and practices; and (iii) company issues related to corporate social responsibility, sustainability and philanthropy. The Corporate Governance Committee Charter is available on our website at
Regulatory & Compliance Committee Meetings Held in 2018: 4 Regulatory & Compliance Committee(1) The Regulatory and Compliance Committee’s primary responsibilities include:
The Committee makes recommendations to the Compensation Committee regarding the extent to which, if any, incentive- based compensation of any executive, senior manager, compliance personnel and/or attorney involved in any significant misconduct resulting in certain government or regulatory action, or other person with direct supervision over such employee, should be reduced, cancelled or recovered. The Regulatory and Compliance Committee Charter is available on our website at
(1) Effective as of the 2019 Annual Meeting, Dr. Ausiello will retire from the Board and as a member of the Audit Committee, the Regulatory and Compliance
Committee and the Science and Technology Committee.
Science & Technology Committee Meetings Held in 2018: 3 Science & Technology Committee(1)
Helen H. Hobbs, M.D.
Chair
Ronald E. Blaylock
Member
W. Don Cornwell
Member
Joseph J. Echevarria
Member
James M. Kilts
Member
Suzanne Nora Johnson
Member
James C. Smith
Member The Science and Technology Committee is responsible for periodically examining management’s strategic direction of and investment in the company’s biopharmaceutical R&D and technology initiatives. Responsibilities include:
The Committee also identifies emerging issues, assesses the performance of R&D leaders, and evaluates the sufficiency of review by external scientific experts. The Science and Technology Committee Charter is available on our website at
(1) Effective as of the 2019 Annual Meeting, Dr. Ausiello will retire from the Board and as a member of the Audit Committee, the Regulatory and Compliance
Committee and the Science and Technology Committee.
Business Leadership & Operations
Nominees with this key skill and experience:
Medicine & Science
Nominees with this key skill and experience:
Healthcare & Pharma
Nominees with this key skill and experience:
Human Capital Management
Nominees with this key skill and experience:
Finance & Accounting
Nominees with this key skill and experience:
International Business
Nominees with this key skill and experience:
Risk Management
Nominees with this key skill and experience:
Government & Public Policy Academia Technology
Nominees with this key skill and experience:
|
